Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenPAAVONEN, J; NAUD, P; HEDRICK, J et al.Lancet (British edition). 2009, Vol 374, Num 9686, pp 301-314, issn 0140-6736, 14 p.Article

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15―25 years with and without serological evidence of previous exposure to HPV-16/18SZAREWSKI, A; POPPE, W. A. J; CASTELLSAGUE, X et al.International journal of cancer (Print). 2012, Vol 131, Num 1, pp 106-116, issn 0020-7136, 11 p.Article

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind, randomised controlled trial. CommentaryKAHN, Jessica A; BURK, Robert D; KITCHENER, Henry C et al.Lancet (British edition). 2007, Vol 369, Num 9580, issn 0140-6736, 2135-2137, 2161-2170 [13 p.]Article